Vivanza Biosciences shareholders approve borrowing limit increase at AGM
- Vivanza Biosciences shareholders approved borrowing limit increase under Section 180(1)(C)
- All ordinary and special resolutions passed at the 44th AGM held on September 11, 2026
- Company issued corrigendum confirming NSDL as e-voting provider, not CDSL
- No changes to voting results or resolution outcomes despite provider name correction

*this image is generated using AI for illustrative purposes only.
Vivanza Biosciences held its 44th Annual General Meeting on September 11, 2026. Shareholders approved key special resolutions, including an increase in borrowing limits under Section 180(1)(C) of the Companies Act, 2013.
The meeting was conducted via video conferencing in compliance with Ministry of Corporate Affairs circulars. The Company Secretary confirmed that the requisite quorum was present throughout the proceedings.
Key Resolutions Approved
Shareholders voted on several ordinary and special business items. The primary focus included governance updates and financial authority expansions.
| Item Type | Resolution Description | Status |
|---|---|---|
| Ordinary | Adoption of FY26 audited standalone and consolidated financial statements | Passed |
| Ordinary | Re-appointment of Mr. Jayendra Mehta as Director | Passed |
| Special | Regularization of Mr. H.A. Parikh as Non-Executive Non-Independent Director | Passed |
| Special | Approval of material Related Party Transactions for FY27 | Passed |
| Special | Adoption of new Memorandum of Association | Passed |
| Special | Adoption of new Articles of Association | Passed |
| Special | Increase in Borrowing Limits under Section 180(1)(C) | Passed |
| Special | Approval for Investments, Loans, and Guarantees under Section 186 | Passed |
| Special | Approval for loans/guarantees to interested Directors under Section 185 | Passed |
Management Commentary
Mr. Jainil Bhatt, Chief Financial Officer, apprised members of the company’s financial performance and future prospects. No questions or queries were raised by shareholders during the session.
The Chairman and Managing Director, Mr. Mehta J.A., presided over the meeting. Other attendees included Independent Directors Mr. Hitesh Rijwani and Ms. Reena Kumari, along with Statutory Auditor Mr. Shivam Soni and Secretarial Auditor Mr. Chintan Patel.
Voting Process and Corrigendum
Remote e-voting was open from September 8 to September 10, 2026. Members could also vote electronically during the AGM. Mr. Chintan K. Patel served as the Scrutinizer for the voting process. The combined results will be disseminated to stock exchanges within 48 hours of the meeting's conclusion.
The company issued a corrigendum on September 12, 2026, clarifying that the e-voting service provider was National Securities Depository Limited (NSDL), not Central Depository Services (India) Limited (CDSL) as erroneously stated in the initial report. The voting percentages and resolution outcomes remain unchanged.
Historical Stock Returns for Vivanza Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.53% | +8.62% | +0.53% | -6.44% | -6.90% | 0.0% |
How will the increased borrowing limits under Section 180(1)(C) influence Vivanza Biosciences' capital allocation strategy for upcoming R&D or expansion projects?
What specific related party transactions were approved for FY27, and how might they impact the company's operational independence or cost structure?
Does the regularization of Mr. H.A. Parikh as a Non-Executive Non-Independent Director signal a shift in corporate governance dynamics or board composition?


































